Aurora-A kinase inhibitor scaffolds and binding modes
Aurora kinases (A–C) belong to the serine/threonine protein kinase family. In recent years, the constitutive or elevated expression of Aurora kinases has been found in cancer cells and oncogene transfected cells. In this review, we summarize the common binding modes of Aurora-A kinase inhibitors, th...
Gespeichert in:
| Veröffentlicht in: | Drug discovery today 2011-03, Vol.16 (5), p.260-269 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 5 |
| container_start_page | 260 |
| container_title | Drug discovery today |
| container_volume | 16 |
| creator | Yan, Aixia Wang, Liyu Xu, Shuyu Xu, Jun |
| description | Aurora kinases (A–C) belong to the serine/threonine protein kinase family. In recent years, the constitutive or elevated expression of Aurora kinases has been found in cancer cells and oncogene transfected cells. In this review, we summarize the common binding modes of Aurora-A kinase inhibitors, the hot spot residues in the binding sites and the privileged inhibitor structures. Our review of the reported chemical scaffolds of Aurora-A kinase inhibitors and their binding modes could provide a useful framework from which new design strategies for inhibitors might be assessed or developed. |
| doi_str_mv | 10.1016/j.drudis.2010.12.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_856172420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S135964461000841X</els_id><sourcerecordid>856172420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-ce7b9aa5cf1439761c5962432bc7e237f7748a6760ddd680deb03c31939f47be3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gchexNPWfGdzEUrxCwpe9Byyyaymbndr0hX896a09uhphuF5Z4YHoUuCpwQTebuc-jj4kKYUb0d0ijE7QmNSqaoUFaPHuWdCl5JzOUJnKS0xJlQLeYpGlBCuqGBjJGZD7KMtZ8Vn6GyCInQfoQ6bPhbJ2abpW58K2_miDp0P3Xux6j2kc3TS2DbBxb5O0NvD_ev8qVy8PD7PZ4vSMU02pQNVa2uFawhnWknihJaUM1o7BZSpRileWakk9t7LCnuoMXOMaKYbrmpgE3Sz27uO_dcAaWNWITloW9tBPyRTCUkU5RRnku9IF_uUIjRmHcPKxh9DsNn6Mkuz82W2vgyhJvvKsav9gaFegT-E_gRl4HoP2OyjbaLtXN5x4JjmFRcyc3c7DrKO7wDRJBegc-BDBLcxvg__f_ILsBGJRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>856172420</pqid></control><display><type>article</type><title>Aurora-A kinase inhibitor scaffolds and binding modes</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Yan, Aixia ; Wang, Liyu ; Xu, Shuyu ; Xu, Jun</creator><creatorcontrib>Yan, Aixia ; Wang, Liyu ; Xu, Shuyu ; Xu, Jun</creatorcontrib><description>Aurora kinases (A–C) belong to the serine/threonine protein kinase family. In recent years, the constitutive or elevated expression of Aurora kinases has been found in cancer cells and oncogene transfected cells. In this review, we summarize the common binding modes of Aurora-A kinase inhibitors, the hot spot residues in the binding sites and the privileged inhibitor structures. Our review of the reported chemical scaffolds of Aurora-A kinase inhibitors and their binding modes could provide a useful framework from which new design strategies for inhibitors might be assessed or developed.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2010.12.003</identifier><identifier>PMID: 21147253</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Animals ; Aurora Kinases ; Binding Sites ; Biological and medical sciences ; Drug Delivery Systems ; Drug Design ; General pharmacology ; Humans ; Medical sciences ; Neoplasms - drug therapy ; Neoplasms - physiopathology ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Protein Binding ; Protein Kinase Inhibitors - pharmacology ; Protein-Serine-Threonine Kinases - antagonists & inhibitors</subject><ispartof>Drug discovery today, 2011-03, Vol.16 (5), p.260-269</ispartof><rights>2010 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-ce7b9aa5cf1439761c5962432bc7e237f7748a6760ddd680deb03c31939f47be3</citedby><cites>FETCH-LOGICAL-c391t-ce7b9aa5cf1439761c5962432bc7e237f7748a6760ddd680deb03c31939f47be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drudis.2010.12.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23948456$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21147253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Aixia</creatorcontrib><creatorcontrib>Wang, Liyu</creatorcontrib><creatorcontrib>Xu, Shuyu</creatorcontrib><creatorcontrib>Xu, Jun</creatorcontrib><title>Aurora-A kinase inhibitor scaffolds and binding modes</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>Aurora kinases (A–C) belong to the serine/threonine protein kinase family. In recent years, the constitutive or elevated expression of Aurora kinases has been found in cancer cells and oncogene transfected cells. In this review, we summarize the common binding modes of Aurora-A kinase inhibitors, the hot spot residues in the binding sites and the privileged inhibitor structures. Our review of the reported chemical scaffolds of Aurora-A kinase inhibitors and their binding modes could provide a useful framework from which new design strategies for inhibitors might be assessed or developed.</description><subject>Animals</subject><subject>Aurora Kinases</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Drug Delivery Systems</subject><subject>Drug Design</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - physiopathology</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Binding</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein-Serine-Threonine Kinases - antagonists & inhibitors</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlb_gchexNPWfGdzEUrxCwpe9Byyyaymbndr0hX896a09uhphuF5Z4YHoUuCpwQTebuc-jj4kKYUb0d0ijE7QmNSqaoUFaPHuWdCl5JzOUJnKS0xJlQLeYpGlBCuqGBjJGZD7KMtZ8Vn6GyCInQfoQ6bPhbJ2abpW58K2_miDp0P3Xux6j2kc3TS2DbBxb5O0NvD_ev8qVy8PD7PZ4vSMU02pQNVa2uFawhnWknihJaUM1o7BZSpRileWakk9t7LCnuoMXOMaKYbrmpgE3Sz27uO_dcAaWNWITloW9tBPyRTCUkU5RRnku9IF_uUIjRmHcPKxh9DsNn6Mkuz82W2vgyhJvvKsav9gaFegT-E_gRl4HoP2OyjbaLtXN5x4JjmFRcyc3c7DrKO7wDRJBegc-BDBLcxvg__f_ILsBGJRg</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Yan, Aixia</creator><creator>Wang, Liyu</creator><creator>Xu, Shuyu</creator><creator>Xu, Jun</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Aurora-A kinase inhibitor scaffolds and binding modes</title><author>Yan, Aixia ; Wang, Liyu ; Xu, Shuyu ; Xu, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-ce7b9aa5cf1439761c5962432bc7e237f7748a6760ddd680deb03c31939f47be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Aurora Kinases</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Drug Delivery Systems</topic><topic>Drug Design</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - physiopathology</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Binding</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein-Serine-Threonine Kinases - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Aixia</creatorcontrib><creatorcontrib>Wang, Liyu</creatorcontrib><creatorcontrib>Xu, Shuyu</creatorcontrib><creatorcontrib>Xu, Jun</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Aixia</au><au>Wang, Liyu</au><au>Xu, Shuyu</au><au>Xu, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aurora-A kinase inhibitor scaffolds and binding modes</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>16</volume><issue>5</issue><spage>260</spage><epage>269</epage><pages>260-269</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>Aurora kinases (A–C) belong to the serine/threonine protein kinase family. In recent years, the constitutive or elevated expression of Aurora kinases has been found in cancer cells and oncogene transfected cells. In this review, we summarize the common binding modes of Aurora-A kinase inhibitors, the hot spot residues in the binding sites and the privileged inhibitor structures. Our review of the reported chemical scaffolds of Aurora-A kinase inhibitors and their binding modes could provide a useful framework from which new design strategies for inhibitors might be assessed or developed.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21147253</pmid><doi>10.1016/j.drudis.2010.12.003</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6446 |
| ispartof | Drug discovery today, 2011-03, Vol.16 (5), p.260-269 |
| issn | 1359-6446 1878-5832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_856172420 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Aurora Kinases Binding Sites Biological and medical sciences Drug Delivery Systems Drug Design General pharmacology Humans Medical sciences Neoplasms - drug therapy Neoplasms - physiopathology Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Protein Binding Protein Kinase Inhibitors - pharmacology Protein-Serine-Threonine Kinases - antagonists & inhibitors |
| title | Aurora-A kinase inhibitor scaffolds and binding modes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A58%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aurora-A%20kinase%20inhibitor%20scaffolds%20and%20binding%20modes&rft.jtitle=Drug%20discovery%20today&rft.au=Yan,%20Aixia&rft.date=2011-03-01&rft.volume=16&rft.issue=5&rft.spage=260&rft.epage=269&rft.pages=260-269&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2010.12.003&rft_dat=%3Cproquest_cross%3E856172420%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=856172420&rft_id=info:pmid/21147253&rft_els_id=S135964461000841X&rfr_iscdi=true |